Finerenone 20 MG Oral Tablet + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Type2diabetes

Conditions

Type2diabetes

Trial Timeline

Jan 18, 2024 → Dec 31, 2025

NCT ID

NCT06244758

About Finerenone 20 MG Oral Tablet + Placebo

Finerenone 20 MG Oral Tablet + Placebo is a phase 3 stage product being developed by Bayer for Type2diabetes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06244758. Target conditions include Type2diabetes.

What happened to similar drugs?

1 of 1 similar drugs in Type2diabetes were approved

Approved (1) Terminated (0) Active (0)

✅Dapagliflozin (Forxiga®) + Placebo matching DapaglifolzinAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06244758	Phase 3	Recruiting	Jan 18, 2024	Dec 31, 2025	Type2diabetes

Competing Products

1 competing product in Type2diabetes

See all competitors

Product	Company	Stage	Hype Score
Dapagliflozin (Forxiga®) + Placebo matching Dapaglifolzin	AstraZeneca	Approved	50